MJ Galindo

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo et al. · The Lancet HIV · 2017 · 96 citations

Protease Inhibitors, Treatment And Prevention, Pharmacology +9

Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive crisis: A case report

Vicente Giner, Maria J. Esteban, MJ Galindo et al. · American Journal of Hypertension · 2002 · 58 citations

Hypertension, Magnetic Resonance Imaging, Active Antiretroviral Therapy +10

First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort

Peré Domingo, Ignacio Suárez-Lozano, Ferràn Torres et al. · Journal of Antimicrobial Chemotherapy · 2008 · 30 citations · Full text

Very low level viraemia and risk of virological failure in treated <scp>HIV</scp>‐1‐infected patients

Ramón Teira, Francesc Vidal, Pepa Muñoz-Sánchez et al. · HIV Medicine · 2016 · 23 citations · Full text

Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV‐1‐infected patients with multidrug‐resistant virus: a multicentre pilot study

Anna Bonjoch, Jose Iribarren, MJ Galindo et al. · HIV Medicine · 2008 · 14 citations · Full text